More than constipation – bowel symptoms in Parkinson’s disease and their connection to gut microbiota Original paper
Researched by:
-
Kimberly Eyer
ID
Kimberly Eyer
Read MoreKimberly Eyer, a Registered Nurse with 30 years of nursing experience across diverse settings, including Home Health, ICU, Operating Room Nursing, and Research. Her roles have encompassed Operating Room Nurse, RN First Assistant, and Acting Director of a Same Day Surgery Center. Her specialty areas include Adult Cardiac Surgery, Congenital Cardiac Surgery, Vascular Surgery, and Neurosurgery.
-
Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. Recent research has focused on the gut microbiota's role in IBS, aiming to identify specific microbial signatures associated with the condition.
-
Kimberly Eyer
Read More
Researched by:
-
Kimberly Eyer
ID
Kimberly Eyer
Read More
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Karen Pendergrass
Location
Finland
Sample Site
Feces
Species
Homo sapiens
What was studied?
The study explored the correlation between bowel symptoms, particularly IBS-like symptoms, and gut microbiota composition in patients with Parkinson’s disease (PD). The primary objective was to assess whether IBS-like symptoms in PD patients were linked to distinct microbial signatures, specifically focusing on alterations in gut bacteria such as Prevotella. The study also aimed to evaluate the broader gastrointestinal dysfunction in PD beyond mere constipation, investigating the microbiota-gut-brain axis’s role in non-motor symptoms.
Who was studied?
The study included 74 patients with Parkinson’s disease (PD) and 75 healthy controls. Participants were assessed for bowel symptoms using the Rome III criteria, and microbiota analysis was performed on fecal samples using 16S rRNA sequencing. The study specifically focused on identifying differences in microbial communities between PD patients with IBS-like symptoms and those without.
What were the most important findings?
The study found that IBS-like symptoms were significantly more prevalent in PD patients (24.3%) compared to controls (5.3%). Importantly, PD patients with IBS-like symptoms exhibited distinct gut microbiota compositions, characterized by a marked reduction in Prevotella and related taxa, which are typically involved in the maintenance of gut barrier integrity and mucosal immunity. In contrast, the genus Bacteroides remained relatively stable. The microbial dysbiosis observed in IBS+ PD patients correlated with more severe non-motor symptoms, such as pain and gastrointestinal distress, which are commonly associated with dysregulation of the gut-brain axis. The results suggest that the gut microbial environment may exacerbate gastrointestinal and non-motor symptoms in PD, providing potential biomarkers for stratification and targeted therapy.
The study also revealed that the presence of IBS-like symptoms in PD patients correlated with a broader spectrum of non-motor symptoms, including increased pain and dysautonomia. These symptoms may reflect a more complex gut-brain axis disruption in PD, where microbial shifts contribute to both local gut dysfunction and central nervous system alterations.
| Parameter | Findings in PD Patients with IBS-like Symptoms |
|---|---|
| IBS Prevalence | 24.3% in PD vs. 5.3% in controls |
| Key Microbial Changes | Marked reduction in Prevotella |
| Gut-Brain Axis Disruption | Linked to more severe non-motor symptoms |
| Non-Motor Symptoms | Increased pain, gastrointestinal distress, dysautonomia |
| Diagnostic Implications | Potential biomarker for identifying at-risk patients |
| Therapeutic Implications | Suggests microbiome-targeted therapies for symptom relief |
What are the greatest implications of this study?
The findings suggest that microbial profiling of PD patients could serve as a diagnostic tool for identifying those at risk of severe gastrointestinal dysfunction and non-motor symptoms. Furthermore, the association between Prevotella depletion and IBS-like symptoms highlights the potential for microbiome-targeted interventions to alleviate both bowel symptoms and broader non-motor manifestations in PD. This supports a growing body of evidence that the microbiota-gut-brain axis plays a significant role in the pathophysiology of Parkinson’s disease, extending beyond motor symptoms to include gut dysbiosis-driven complications. The study advocates for integrating microbiome analysis into PD management to tailor dietary, probiotic, and therapeutic interventions that restore microbial balance and potentially improve patient outcomes.
Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. Recent research has focused on the gut microbiota's role in IBS, aiming to identify specific microbial signatures associated with the condition.
Parkinson’s Disease
Parkinson’s disease is increasingly recognized as a systemic disorder involving coordinated disturbances across the gut–brain axis, rather than a condition confined to dopaminergic neurodegeneration alone. Converging evidence implicates gut dysbiosis, altered microbial metabolites, impaired intestinal barrier integrity, and metal dyshomeostasis as upstream drivers of neuroinflammation and alpha-synuclein pathology. These interconnected microbiome, metabolomic, and metallomic signals provide a mechanistic framework for understanding disease initiation, progression, and therapeutic targeting beyond the central nervous system.